Bioavailability vs. Outcomes: What Really Drives Ketamine Results

What Bioavailability Means for Ketamine Outcomes

Higher bioavailability does not automatically translate to better therapeutic results. Bioavailability refers to the percentage of a drug that reaches systemic circulation and becomes available to produce an effect. Different delivery routes yield different absorption ranges based on how the body processes the medicine at each site.

After absorption, the liver converts ketamine into an active metabolite called norketamine via the cytochrome P450 enzyme system. Routes passing through the gastrointestinal tract, such as oral or partially sublingual delivery, undergo first-pass metabolism. The digestive process reduces the amount of active parent compound reaching the brain. Oral ketamine has a half-life of approximately two to four hours, while norketamine remains in the system longer. Daily low-dose oral protocols are particularly affected by first-pass metabolism, and the published response, remission, and durability data needed to evaluate them comparatively does not yet exist.

Published data indicates that higher absorption does not inherently dictate the final result, although direct comparisons across treatment modalities should be interpreted with caution because study designs, patient populations, and outcome measures differ. In the largest real-world study of any ketamine intervention published to date, an analysis of 11,441 patients receiving sublingual ketamine (approximately 30% bioavailability) achieved a 56.4% response rate and 61.4% clinically significant change rate by week four, with a Cohen's d of 1.46.¹ This effect size matches or exceeds the pooled effect sizes reported in IV ketamine meta-analyses, despite IV's 100% bioavailability.²

If absorption were the primary determinant of success, intravenous delivery would produce substantially better outcomes than sublingual delivery. The published data does not support that conclusion, indicating that other treatment variables play an outsized role.

Bioavailability directly influences several specific factors:

• Onset speed: Higher absorption routes typically act faster.
• Dose calculation: Providers adjust the prescribed amount based on expected absorption.
• Session predictability: Routes bypassing the digestive system offer more consistent initial effects.

Bioavailability does not determine the following factors on its own:

• Therapeutic outcome: Symptom relief depends on the full care protocol.
• Durability: Long-term benefits rely heavily on neuroplasticity and integration.
• Safety: Safety is a function of clinical screening and supervision.

Ketamine Routes of Administration and Typical Bioavailability

Providers can administer ketamine through several different routes, each offering a distinct absorption range, onset profile, and care context. The selected route serves as one part of a broader care design rather than a standalone quality indicator. Each pathway carries trade-offs in absorption consistency, onset speed, and care setting requirements.

clinical professionals calibrate the prescribed dose to the specific administration method. Providers calibrate the prescribed dose to each route's known bioavailability, a process detailed in the Dose Calibration section below.

Intravenous Ketamine

An intravenous infusion sends the medicine directly into the bloodstream via a controlled drip in a supervised setting. Bioavailability is effectively 100% because the drug bypasses all absorption barriers. The onset of effects is rapid, typically beginning within 1 to 2 minutes.

Researchers often use intravenous delivery as the pharmacokinetic reference point in clinical studies. Intravenous therapy suits individuals who want maximum dose precision and feel comfortable receiving care in a clinical facility. The process requires in-person visits and continuous monitoring throughout the infusion.

Intramuscular Ketamine

Intramuscular delivery involves injecting the medicine into muscle tissue, typically within a clinical facility. The bioavailability for intramuscular delivery is approximately 93%. The onset of effects is slightly slower than intravenous delivery, usually beginning within a few minutes.

Intramuscular delivery is a common clinical route that does not require the placement of an intravenous line. The injection method simplifies the administration process compared to a controlled drip. Intramuscular delivery suits individuals seeking high absorption in a supervised setting without the requirements of continuous intravenous access.

Subcutaneous Ketamine

Subcutaneous injection places the medicine into the fatty tissue just beneath the skin, typically using a small insulin-type needle. Bioavailability is generally reported in the range of 64% to 66%, based on population pharmacokinetic data from peer-reviewed clinical research.⁶ Effects typically appear within approximately five minutes.

Subcutaneous delivery can be administered outside a traditional facility under proper clinical oversight. The route suits individuals who want high, consistent bioavailability with a simpler injection method than intravenous therapy.

Sublingual Ketamine

Sublingual dosing uses a tablet or orally disintegrating tablet (ODT) held against the oral mucosa for a specified period before the remaining material is spit out. Bioavailability typically ranges from 25% to 35% because a portion of the dose is inevitably swallowed. Swallowed medicine undergoes first-pass metabolism in the liver.

Some at-home sublingual protocols use a hold-and-spit technique to standardize absorption time and reduce swallowed-fraction variability. Patients who prefer needle-free administration and value the comfort of their own environment often gravitate toward sublingual delivery. Session-to-session variability can be somewhat higher than injection-based routes, making precise dosing calibration essential.

Intranasal Ketamine

Intranasal delivery sends the medicine as a nasal spray absorbed through the nasal mucosa. Bioavailability is typically reported in the range of 25% to 50%. Spravato (esketamine nasal spray) is the only FDA-approved ketamine-derived product for treatment-resistant depression.

Spravato is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) program. The REMS program requires in-clinic dosing and post-dose monitoring. This route is typically recommended when a physician determines it is the appropriate option, particularly within the Spravato framework.

What Actually Drives Ketamine Treatment Outcomes

Treatment outcomes depend on a constellation of factors that surround and support the pharmacological experience, not just how much medicine reaches the bloodstream. Bioavailability is simply one pharmacokinetic input. What happens before, during, and after the session shapes whether that input translates into durable symptom relief.

When dose calibration, environment, and post-session integration are built into the care protocol, the bioavailability gap between routes narrows significantly. Published literature shows that sublingual response rates of 56.4% approach those reported in intravenous studies when these framework variables are accounted for.^1,2

Dose Calibration and clinical Titration

The prescribing clinician titrates the dose to the specific delivery route. Because absorption differs by route, the prescribed amount for sublingual delivery is adjusted upward relative to an intravenous dose so both achieve a therapeutic effect. Bioavailability serves as an input used for dosing calculations, not an output of care quality.

The hold-and-spit protocol described above is one example of how technique-level controls reduce absorption variability during sublingual sessions. Dose adjustments happen across sessions based on individual response, which further decouples bioavailability from the final outcome. Clinicians use sub-anesthetic, individually calibrated dosing to find the optimal level that promotes neuroplasticity.

Set and Setting

"Set" refers to your mindset, expectations, and psychological preparation before a session. Your "setting" is the physical and social environment where the session takes place. Foundational research shows that set and setting are top predictors of outcomes in psychedelic-assisted and ketamine-assisted therapy.⁴

A familiar, comfortable environment combined with adequate preparation can support deeper therapeutic engagement. The importance of environment explains why at-home care models can produce outcomes comparable to facility-based settings when properly managed.⁵

Integration and Therapeutic Support

Integration is the process of making sense of the ketamine experience and translating insights into lasting changes in thought patterns, behavior, and daily life. The process can include guided coaching, journaling, reflection exercises, and group processing. Ketamine opens a neuroplastic window, but without integration, that window may close without producing durable change.

Peer-reviewed evidence highlights the role of integration and psychotherapy-augmented protocols in sustaining positive outcomes.⁵ Self-directed practices like journaling are accessible options for everyone. Supervised support through coaching and group circles provides an additional layer that reinforces the durability of symptom relief over time.

Conclusion

Higher bioavailability does not inherently mean better ketamine results. Absorption rates affect how providers calculate dosing and predict onset, but published data shows that protocol-driven sublingual programs produce response rates (56.4%) comparable to those reported in intravenous studies.^1,2 What truly determines outcomes is the full treatment system.

Dose calibration to the route, preparation, environment, clinical oversight, and integration support drive the therapeutic process. You should evaluate ketamine therapy based on the quality of the care model, not bioavailability alone. Choosing ketamine should be a collaborative decision with your provider to personalize the approach to your goals and health history.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.